title: 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies.
abstract: A number of important studies were presented at the Society for Neuro-Oncology annual meeting in Montréal, Canada, on 18-21 November 2010. Cediranib as monotherapy or in combination with lomustine did not show increased efficacy when compared with lomustine alone in patients with recurrent glioblastoma (GBM). Addition of temozolomide (TMZ) or irinotecan (CPT) to bevacizumab (BEV) in patients with recurrent GBM was well tolerated, with similar efficacy to BEV alone. The addition of BEV to radiation and TMZ in newly diagnosed GBM improved progression-free survival but did not improve overall survival. TMZ alone may be a reasonable approach in elderly GBM patients with poor performance status. Two Phase II trials with sunitinib and vatalanib showed a hint of activity in patients with recurrent or progressive meningiomas.
authors.affiliation: Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, S73, Cleveland, OH 44195, USA. ahluwam@ccf.org
authors.forename: Manmeet S
authors.initials: MS
authors.lastname: Ahluwalia
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008579:Meningioma / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents